SEC Tracker
Get the app

Clearmind Medicine CMND

Clearmind Announces Patent Publication in Japan

Foreign issuer report

Form
6-K
Filed
Importance
Routine
  1. Published patent application covers 3-MMC-based treatment of dyskinesia.
  2. Includes combinations with Palmitoylethanolamide (PEA).
  3. Part of collaboration with NeuroThera Labs Inc.

Written from the 6-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Clearmind Medicine files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Same SIC code (2834) and public float not reported.

  1. Acura Pharmaceuticals ACUR
  2. Ayala Pharmaceuticals ADXS
  3. Ampio Pharmaceuticals AMPE
  4. Alterity Therapeutics ATHE
  5. Adhera Therapeutics ATRX